Pharmaceutical firms from Europe, Japan, South Korea and the United States are investing in the development of medications and treatments derived from traditional Chinese medicine. GlaxoSmithKline, for example, recently announced a traditional Chinese medicine program based in Shanghai that will target both a Chinese and global market. "Our priority is to transform TCM from an experience-based practice to evidence-based medicines through innovation and differentiation," said Jingwu Zang, head of R&D for GlaxoSmithKline in China.

Related Summaries